

PATENTS
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sheng Lou, et al.

Serial No.: 10/714,689

Filed: November 17, 2003

For: MONOCLONAL ANTIBODIES TO
HUMAN IMMUNODEFICIENCY VIRUS AND
USES THEREOF

Examiner: JEFFERY S. PARKIN

Group Art Unit: 1648

Attorney Docket No.: 6755.US.D1

Confirmation No. 5738

**Certificate of Mailing or TRANSMISSION Under
37 CFR 1.8**

I hereby certify that this correspondence is being
electronically transmitted with the USPTO Web-based
electronic filing system, facsimile transmitted or
deposited with the United States Postal Service with
sufficient postage as first class mail in an envelope
addressed to: Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450

Date of Deposit/Transmission: May 16, 2008

/Audrey L. Bartnicki/

Audrey L. Bartnicki

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF BIOLOGICAL CULTURE DEPOSIT

Applicants' undersigned attorney submits:

1. That I, Audrey Bartnicki, am an in-house patent attorney for Abbott Laboratories, the assignee of the above-referenced patent application.

2. That, as stated on page 17, lines 17-32 of the subject application's Detailed Description (modified by Preliminary Amendment), the hybridoma cell lines producing monoclonal antibodies **120A-270, 115B-151, 117-289, 103-350, 115B-303 and 108-394** referred to in the application have been deposited as follows under the provisions of the Budapest Treaty with American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110:

The present invention not only includes the monoclonal antibodies referred to above but also includes the novel hybridoma cell lines which produce these

antibodies. More specifically, the cell line PTA-3890 (deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110 under the terms of the Budapest Treaty on Dec. 4, 2001) produces monoclonal antibody 120A-270, the cell line PTA-2809 produces monoclonal antibody 115B-151, the cell line PTA-2806 produces monoclonal antibody 117-289, the cell line PTA-2808 produces monoclonal antibody 103-350, the cell line PTA-2807 produces monoclonal antibody 108-394, and the cell line PTA-2810 produces monoclonal antibody 115B-303. The cell lines producing the last five antibodies noted were deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110 under the terms of the Budapest Treaty on December 13, 2000 and were accorded the ATCC accession numbers noted above.

3. That all restrictions upon public access to the deposits described in paragraph 2 will be irrevocably removed upon the grant of a patent on the application, and the deposit will be replaced if viable samples cannot be dispensed, as required, by the depository.

4. That all statements made on information and belief are believed to be true, and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and such willful false statements may jeopardize the validity of the subject patent application or patent issuing thereon.

Respectfully submitted,
Sheng Lou, et al.

/Audrey L. Bartnicki/

23492

ABBOTT LABORATORIES
Telephone: (847) 938-3440
Facsimile: (847) 938-2623

Audrey L. Bartnicki
Registration No. 40,499
Attorney for Applicants